Citigroup Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $41

Citigroup analyst Yigal Nochomovitz has downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from a Buy rating to Neutral. The price target for the stock has also been reduced from $44 to $41.